|   | 
        
            
         | 
          | 
        
        
        
            | 
                
             | 
         
        
             | 
         
        
            
            
            
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    »çÀÌÅ©·Ï½ºÁ¤  CYCLOX TAB.[Aluminum hydroxide gel(dried) , Dicyclomine HCl , Magnesium Oxide]  
                    
                 | 
               
              
                | 
                     ÀϹÝÀǾàǰ | ºñ±Þ¿©  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |  
                              
                                  | 
                                   | 
                               
            
            
                
            
            
              
            
                            
              
                                                     
            
            
   |  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        [A24600441]  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \0 ¿ø/1Á¤(2006.11.01)(ÇöÀç¾à°¡) 
            \20 ¿ø/1Á¤(2002.11.29)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ¹é»öÀÇ ¿øÇüÁ¤Á¦  
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    500T | 
   
  
  
  
  
  
  
  
  
  
  
  
  
   
    | º¸°ü¹æ¹ý | 
    ±â¹Ð¿ë±â | 
   
  
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
      
        [Á¶È¸]
     | 
      
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      À§±Ë¾ç, ½ÊÀÌÁöÀå±Ë¾ç, ±Þ¸¸¼ºÀ§¿°, À§Åë, À§»ê°ú´ÙÁõ 
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Dicyclomine]
      
      
      
      
     | 
   
  
  
  
  
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      [ÁÖ¼ººÐÄÚµå:284900ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷] 
¼ºÀÎ 1ȸ 1Á¤ 1ÀÏ 3ȸ ½Ä°£ ¶Ç´Â ½ÄÈÄ¿¡ º¹¿ëÇÑ´Ù.     
      	    
     | 
   
  
  
  
  
  
  
   
    | °æ°í | 
    
      ÀÌ ¾à¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Â Àΰø°¨¹ÌÁ¦ ¾Æ½ºÆÄŽÀº ü³»¿¡¼ ºÐÇØµÇ¾î Æä´Ò¾Ë¶ó´ÑÀ¸·Î ´ë»çµÇ¹Ç·Î, Æä´Ò¾Ë¶ó´ÑÀÇ ¼·Ã븦 ±ÔÁ¦ÇÒ Çʿ䰡 ÀÖ´Â À¯Àü¼ºÁúȯÀÎ Æä´ÒÄÉÅæ´¢Áõ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¸» °Í
     | 
   
  
  
  
  
   
    | ±Ý±â | 
    
      - ³ì³»Àå ȯÀÚ
 - Àü¸³¼± ºñ´ë¿¡ ÀÇÇÑ ¹è´¢Àå¾Ö°¡ Àִ ȯÀÚ
 - ½ÉÇÑ ½ÉÁúȯ ȯÀÚ
 - ¸¶ºñ¼º ÀåÆó¼âÁõ ȯÀÚ
 - Åõ¼®¿ä¹ýÀ» ¹Þ°í Àִ ȯÀÚ(Àå±âÅõ¿©¿¡ ÀÇÇØ ¾Ë·ç¹Ì´½ °ñÁõµîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
    
 
  | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    - Àü¸³¼± ºñ´ë ȯÀÚ
 - °©»ó¼± ±â´É Ç×ÁøÁõ ȯÀÚ
 - ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ(Áßµ¶¼º °Å´ë °áÀåÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
 - ½ÅÀå¾Ö ȯÀÚ(Àå±âÅõ¿©¿¡ ÀÇÇØ ¾Ë·ç¹Ì´½ ³úÁõ, ¾Ë·ç¹Ì´½ °ñÁõµîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î Á¤±âÀûÀ¸·Î Ç÷Áß ¾Ë·ç¹Ì´½, ÀÎ, Ä®½·, ¾ËÄ«¸®Æ÷½ºÆÄŸÁ¦ µîÀ» ÃøÁ¤ÇÑ´Ù.)
 - ½É±â´ÉÀå¾Ö(°ü»óµ¿¸Æ¼º ½ÉÀ庴, ¿ïÇ÷¼º½ÉºÎÀü, ºÎÁ¤¸Æ, °íÇ÷¾Ð µî)ȯÀÚ
 - ¼³»çȯÀÚ
 - °í¸¶±×³×½·Ç÷Áõ ȯÀÚ
 - Àλ꿰°áÇÌ È¯ÀÚ
 - °í¿Âȯ°æ¿¡ Àִ ȯÀÚ
 - °í·ÉÀÚ(°í·ÉÀÚ¿¡ ´ëÇÑ Åõ¿©Ç× ÂüÁ¶)
 - ÀÚÀ²½Å°æÁúȯ ȯÀÚ, °£Áúȯ ȯÀÚ
 - °ú¹ÎÁõÀ» Æ÷ÇÔÇÏ´Â ¾à¹° ƯÀÌüÁú ȯÀÚ
 
  | 
   
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
      - ´« :
   ¶§¶§·Î ½ÃÁ¶Àý Àå¾Ö, ¾È³»¾Ð Ç×Áø µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
Á¤½Å ½Å°æ°è : ¶§¶§·Î µÎÅë,µÎÁß,¾îÁö·¯¿ò,ºÒ¸éÁõ ¶Ç´Â Á¹À½ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼Òȱâ°è : ±¸°¥ ,º¯ºñ ¶§¶§·Î ¼³»ç,¹±Àº º¯,±¸¿ª,±¸Åä,º¹ºÎÆØ¸¸,ºÒÄè°¨, ½Ä¿åºÎÁø µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼øÈ¯±â°è : ¶§¶§·Î ½É°èÇ×ÁøµîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
°ú¹ÎÁõ: µå¹°°Ô ¹ßÁø, ÀÌ»ó°í¿, °¡·Á¿òÁõ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù
ºñ´¢±â°è : µå¹°°Ô ¹è´¢Àå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
´ë»çÀÌ»ó : ¹èÇÕ¼ººÐÀÎ »êȸ¶±×³×½·ÀÇ Àå±â°£ ´ë·®Åõ¿©¿¡ ÀÇÇØ °í¸¶±×³×½·Ç÷ÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ Çϰí ÀÌ»óÀÌ ¾ÈÁ¤µÇ´Â °æ¿ì¿¡´Â °¨·® ¶Ç´Â ÈÞ¾à µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
Àå±âÅõ¿© : ¹èÇÕ¼ººÐÀÎ °ÇÁ¶ ¼ö»êȾ˷ç¹Ì´½°ÖÀÇ Àå±â°£ Åõ¿©¿¡ ÀÇÇØ ¾Ë·ç¹Ì´½³úÁõ,¾Ë·ç¹Ì´½°ñÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
±âŸ : ¶§¶§·Î ±Çۨ,Å»·Â°¨,¸ð¾ç±Ù¸¶ºñ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
          
     | 
   
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
    Á¹À½,½Ã¾ß¸ù·Õ µîÀÌ ÀϾ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ ¾àÀ» Åõ¿©¹Þ°í Àִ ȯÀÚ´Â ÀÚµ¿Â÷¿îÀü µî À§ÇèÀÌ ¼ö¹ÝµÇ´Â ±â°èÁ¶ÀÛÀ» ÇÏÁö ¾Êµµ·Ï ÁÖÀÇÇÑ´Ù. | 
   
  
  
  
    
   
    | »óÈ£ÀÛ¿ë | 
    - ´ÙÀ½ ¾à¹°°úÀÇ º´¿ëÅõ¿©¿¡ ÀÇÇØ ÀÌ ¾à ÁßÀÇ ¿°»ê µð»çÀÌŬ·Î¹ÎÀÇ ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖ´Ù.
 
 - »ïȯ°è Ç׿ì¿ïÁ¦,Æä³ëÄ¡¾ÆÁø°è ¾à¹°,MAO¾ïÁ¦Á¦
 - Åׯ®¶ó»çÀÌŬ¸°°è Ç×»ý¹°ÁúÀÇ Èí¼ö¸¦ ÀúÇØÇÒ ¼ö ÀÖÀ¸¹Ç·Î º´¿ëÅõ¿©ÇÏÁö¾Ê´Â´Ù.
 - ÀÌ ¾àÀÇ Èí¼öÀÛ¿ë ¶Ç´Â ¼ÒȰü³»,ü¾×ÀÇ PH»ó½Â¿¡ ÀÇÇØ º´¿ë¾à¹°ÀÇ Èí¼ö¹è¼³¿¡ ¿µÇâÀ» ÁÙ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
 - ´Ù·®ÀÇ ¿ìÀ¯, Ä®½·Á¦Á¦¿Í º´¿ëÅõ¿©½Ã ¿ìÀ¯¾ËÄ«¸®ÁõÈıºÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
 
  | 
   
  
  
  
  
  
  
  
  
  
   
    | ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© | 
    
      
       
      °í·ÉÀÚ¿¡ ´ëÇÑ Ç×Äݸ° ÀÛ¿ë¿¡ ÀÇÇÑ ±¸°¥, ¹è´¢Àå¾Ö, º¯ºñ, ¾È³»¾ÐÇ×Áø µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  		
  
  
   
    | º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ | 
    ±â¹Ð¿ë±â | 
   
  	
  
  
    
   
    | ±âŸ | 
    °í·ÉÀÚ¿¡´Â Ç×Äݸ° ÀÛ¿ë¿¡ ÀÇÇÑ ±¸°¥, ¹è´¢Àå¾Ö,º¯ºñ,¾È³»¾ÐÇ×Áø µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. | 
   
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
       
  
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        	
					  
					
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  
   
    | º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ | 
    
      [º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
     | 
   
  	
  
  
  
   
    | º¹¾à¶óº§ | 
    
    
    
      | À̹ÌÁö | 
      º¹¾à¼³¸í | 
     
    
    
        | 
      º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. | 
     
    
       | 
     
    
    
        | 
      ¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. | 
     
    
       | 
     
    
     |  
    
      
	
	  
            | *  | 
	    º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. | 
	   
	  
            | *  | 
	    º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. | 
	   
	  
            | *  | 
	    ±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. | 
	   
	   
     |   
     | 
   
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | µ¶¼ºÁ¤º¸ | 
    Magnesium¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
  Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do  | 
   
  
   
    | Mechanism of Action | 
    
       Dicyclomine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).
  Magnesium¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Not Available 
     | 
   
  
   
    | Pharmacology | 
     
       Dicyclomine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dicyclomine is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Dicyclomine is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Dicyclomine inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions. 
     | 
   
  
   
    | Protein Binding | 
    
       Dicyclomine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ >99% 
     | 
   
  
   
    | Half-life | 
    
       Dicyclomine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available 
     | 
   
  
   
    | Absorption | 
    
       Dicyclomine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available 
     | 
   
  
   
    | Pharmacokinetics | 
    
       Magnesium OxideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
-  Èí¼ö : °øÀå, ȸÀå¿¡¼ ´Éµ¿, ¼öµ¿ Èí¼ö
 
 -  »çÇÏÀÛ¿ë ¹ßÇö : 4-8 ½Ã°£ 
 
 - ÃѴܹé°áÇÕÀ² : 33%
 
 -  ¼Ò½Ç : Èí¼öµÈ ¸¶±×³×½·Àº ½Å¼ÓÇÏ°Ô ½ÅÀå ¹è¼³, Èí¼öµÇÁö ¾ÊÀº ¸¶±×³×½·Àº ´ëº¯ ¹è¼³
   
 
	 Aluminum hydroxide gel(dried)ÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- ÀÛ¿ë¹ßÇö½Ã°£ : 10-15 ºÐ 
	
 - ÀÛ¿ëÁö¼Ó½Ã°£ : °øº¹½Ã : 30 ¡¾ 10 ºÐ 
	½ÄÈÄ 1½Ã°£ Åõ¿©½Ã : 1-3 ½Ã°£  
	 - Èí¼ö : ½ÅºÎÀüÀÇ °æ¿ì Èí¼öµÇ¾î Ç÷Áß aluminum ³óµµ°¡ Áõ°¡µÉ ¼ö ÀÖ´Ù.  
   
	 
	 Dicyclomine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- ÀÛ¿ë¹ßÇö½Ã°£ : 1-2½Ã°£
	
 - ÀÛ¿ëÁö¼Ó½Ã°£ : 4½Ã°£±îÁö
	
 - Èí¼ö : °æ±¸ : Àß Èí¼öµÊ
	
 - ºÐÆ÷ : Vd : 3.65 L/kg 
 - ´ë»ç : ´ë»ç Å
	
 - ¹Ý°¨±â 
	
		- Ãʱ⠻ó(phase) : 1.8½Ã°£  
		
 - ¸»±â »ó : 9-10½Ã°£
	
  
	 - ¼Ò½Ç : ¹Ìº¯Èü·Î¼ ¼Ò·®¸¸ÀÌ ´¢¸¦ ÅëÇØ ¹è¼³µÊ
  
 
	
     | 
   
  
   
    | Toxicity | 
    
       Dicyclomine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available 
     | 
   
  
   
    | Drug Interactions | 
    
       Dicyclomine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Donepezil	Possible antagonism of actionGalantamine	Possible antagonism of actionRivastigmine	Possible antagonism of actionHaloperidol	The anticholinergic increases the risk of psychosis and tardive dyskinesia
  Magnesium¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alendronate	Formation of non-absorbable complexesCiprofloxacin	Formation of non-absorbable complexesClodronate	Formation of non-absorbable complexesDemeclocycline	Formation of non-absorbable complexesDoxycycline	Formation of non-absorbable complexesEnoxacin	Formation of non-absorbable complexesEtidronic acid	Formation of non-absorbable complexesGatifloxacin	Formation of non-absorbable complexesGemifloxacin	Formation of non-absorbable complexesGrepafloxacin	Formation of non-absorbable complexesIbandronate	Formation of non-absorbable complexesLevofloxacin	Formation of non-absorbable complexesLomefloxacin	Formation of non-absorbable complexesMethacycline	Formation of non-absorbable complexesMinocycline	Formation of non-absorbable complexesMoxifloxacin	Formation of non-absorbable complexesNorfloxacin	Formation of non-absorbable complexesOfloxacin	Formation of non-absorbable complexesOxytetracycline	Formation of non-absorbable complexesPefloxacin	Formation of non-absorbable complexesRisedronate	Formation of non-absorbable complexesTrovafloxacin	Formation of non-absorbable complexesTetracycline	Formation of non-absorbable complexesTemafloxacin	Formation of non-absorbable complexesAmprenavir	The antiacid decreases the absorption of amprenavirChloroquine	The antiacid decreases the absorption of chloroquineAtazanavir	This gastric pH modifier decreases the levels/effects of atazanavirDelavirdine	The antiacid decreases the absorption of delavirdineDihydroquinidine barbiturate	The antiacid decreases the absorption of quinidineFosamprenavir	The antiacid decreases the absorption of amprenavirIndinavir	The antiacid decreases the absorption of indinavirQuinidine	The antiacid decreases the absorption of quindineQuinidine barbiturate	The antiacid decreases the absorption of quinidinePolystyrene sulfonate	Risk of alkalosis in renal impairmentRosuvastatin	The antiacid decreases the absorption of rosuvastatin 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Dicyclomine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take this medication 30 minutes before meals. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Dicyclomine¿¡ ´ëÇÑ Description Á¤º¸ A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms. [PubChem]
  Magnesium¿¡ ´ëÇÑ Description Á¤º¸ Magnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents. 
     | 
   
  
   
    | Dosage Form | 
    
       Dicyclomine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule	OralSolution	IntramuscularSyrup	OralTablet	Oral
  Magnesium¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol	OralCapsule	OralLiquid	IntramuscularLiquid	IntravenousLiquid	OralOintment	TopicalPellet	OralPowder	OralSolution	IntramuscularSolution	IntravenousSolution	OralSolution / drops	OralSuspension	OralSyrup	OralTablet	Oral 
     | 
   
  
   
    | Drug Category | 
    
       Dicyclomine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anticholinergic AgentsAntimuscarinicsAntispasmodicsMuscarinic AntagonistsParasympatholytics
  Magnesium¿¡ ´ëÇÑ Drug_Category Á¤º¸ Not Available 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Dicyclomine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
  Magnesium¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ [Mg++] 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Dicyclomine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
  Magnesium¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ [Mg++] 
     | 
   
  
   
    | InChI Identifier | 
    
       Dicyclomine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
  Magnesium¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/Mg/q+2 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Dicyclomine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate
  Magnesium¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ magnesium(+2) cation 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2016-05-10
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  [ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â]       Á¦¸ñ ¾øÀ½ 
 
    
    2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
    
    1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ  º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
          
    
    
    
    2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
 
 
 
   
  |  
             
             | 
         
         
         | 
         |